Cartesian Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cartesian Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- RNAC
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001453687
Board of directors
-
Aymeric Sallin · DirectorSince 2023
-
Carrie Smith Cox · DirectorSince 2023
-
Carsten Brunn · Director · President and CEOSince 2023
-
Goran Ando · DirectorSince 2023
-
Kemal Malik · DirectorSince 2024
-
Michael Singer · DirectorSince 2023
-
Murat Kalayoglu · DirectorSince 2023
-
Nishan M. DeSilva · DirectorSince 2023
-
Patrick J. Zenner · DirectorSince 2023
-
Scott Dunseth Myers · DirectorSince 2023
-
Timothy A. Springer · DirectorSince 2023
-
Timothy C. Barabe · DirectorSince 2023
Chief executives
Carsten Brunn
· President and CEO
Dates unknown
Board connections
4 of this board's directors also sit on 7 other boards.
- via Goran Ando
- via Carrie Smith Cox
- via Carrie Smith Cox
- via Timothy A. Springer
- via Carrie Smith Cox
- via Scott Dunseth Myers
- via Scott Dunseth Myers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 26, 2024 | Michael Singer Director | Gift | −20,000 | — | — |
| Dec 26, 2024 | English Emily Officer (SVP, Head of Manufacturing) | Option exercise | +7,650 | $3.30 | $25,245 |
| Dec 23, 2024 | Timothy A. Springer Director, 10% owner | Open-market purchase | +5,181 | $19.00 | $98,439 |
| Dec 20, 2024 | Timothy A. Springer Director, 10% owner | Open-market purchase | +21,800 | $18.94 | $412,892 |
| Dec 19, 2024 | Timothy A. Springer Director, 10% owner | Open-market purchase | +11,303 | $17.39 | $196,559 |
| Dec 19, 2024 | Timothy A. Springer Director, 10% owner | Open-market purchase | +10,529 | $18.35 | $193,207 |
| Dec 19, 2024 | Timothy A. Springer Director, 10% owner | Open-market purchase | +3,376 | $18.93 | $63,908 |
| Dec 10, 2024 | Kurtoglu Metin Officer (Chief Technology Officer) | Option exercise | +2,901 | $1.41 | $4,090 |
| Dec 10, 2024 | Kurtoglu Metin Officer (Chief Technology Officer) | Open-market sale | −2,901 | $24.35 | $70,639 |
| Dec 9, 2024 | Kurtoglu Metin Officer (Chief Technology Officer) | Option exercise | +10,763 | $1.41 | $15,176 |
| Dec 9, 2024 | Kurtoglu Metin Officer (Chief Technology Officer) | Open-market sale | −6,224 | $25.26 | $157,218 |
| Dec 9, 2024 | Kurtoglu Metin Officer (Chief Technology Officer) | Open-market sale | −4,539 | $25.83 | $117,242 |
| Sep 25, 2024 | Timothy A. Springer Director, 10% owner | Option exercise | −1,636,832 | — | — |
| Sep 25, 2024 | Timothy A. Springer Director, 10% owner | Option exercise | +1,636,832 | — | — |
| Sep 25, 2024 | Timothy A. Springer Director, 10% owner | Option exercise | −721,361 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.